logo.jpg
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
June 11, 2024 08:20 ET | Processa Pharmaceuticals, Inc.
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses...
22157.jpg
Oncology Nutrition Market Experiences Growth with Rise in Personalized and Immuno-nutrition Trends
January 22, 2024 21:28 ET | Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Oncology Nutrition Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The recent comprehensive analysis within...
Medicovestor Rectangle.PNG
Medicovestor, Inc announces the completion of an oversubscribed Seed Financing round to advance its novel Antibody Drug-Conjugate (ADC) platforms
November 20, 2023 10:00 ET | Medicovestor Inc
Medicovestor excels in oversubscribed Seed funding for its novel Anti-Drug Conjugate (ADC) platforms, gearing up for Series A in H1 2024.
Cancer Advances logo.jpg
Cancer Advances, Inc. Announces Issuance of New U.S. Patent
February 28, 2023 02:00 ET | Cancer Advances Inc
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S....
endoluminal-suturing-devices-market-size.jpg
The Worldwide Endoluminal Suturing Devices Industry is Expected to Reach $152.3 Million by 2028
November 11, 2022 04:33 ET | Research and Markets
Dublin, Nov. 11, 2022 (GLOBE NEWSWIRE) -- The "Global Endoluminal Suturing Devices Market Size, Share & Industry Trends Analysis Report By Application (Gastrointestinal Surgery, Bariatric...
22157.jpg
Global Oncology Nutrition Market Report 2022: A $2.13 Billion Market in 2026 Featuring B. Braun Melsungen, Danone India, Abbott Laboratories, Nestle, Victus
October 06, 2022 06:13 ET | Research and Markets
Dublin, Oct. 06, 2022 (GLOBE NEWSWIRE) -- The "Oncology Nutrition Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global oncology nutrition market is...
22157.jpg
Tyrokinse Kinase Inhibitors in the Global Oncology Market 2021: Market Leaders by Indication and Product
November 05, 2021 05:58 ET | Research and Markets
Dublin, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The "Oncology Markets for Tyrokinse Kinase Inhibitors" report has been added to ResearchAndMarkets.com's offering. Traditional cancer therapy has focused...
Cancer Advances logo.jpg
Cancer Advances, Inc. Announces Publication, “Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model" in Cancer Prevention Research
August 24, 2021 10:30 ET | Cancer Advances Inc
DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces a new publication in...
logo.jpg
Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer
August 04, 2021 08:30 ET | Processa Pharmaceuticals, Inc.
Processa’s Phase 1b open label, multicenter trial is currently enrolling patients who have advanced, relapsed GI cancer that are refractory or intolerant to other therapies and are candidates for...
New Logo.png
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstracts at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
April 28, 2021 12:35 ET | Provectus Biopharmaceuticals Inc.
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors (NCT02693067) — Systemic administration of PV-10 for treatment of solid tumor...